Problems pertaining to the development of individual therapy based on the achievements of modern pharmacogenetics and pharmacogenomics, as well as the safety of using drugs from various pharmacological groups in patients belonging to different ethnical groups (with the corresponding features of metabolism) are considered. The terms "pharmacogenetics" and "pharmacogenomics" are discussed in connection to the significance of genetic polymorphism (or single nucleotide polymorphism) in determining of the individual sensitivity with respect to certain drugs.